Edition:
United States

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

6.07USD
26 Jul 2017
Change (% chg)

$-0.02 (-0.33%)
Prev Close
$6.09
Open
$6.11
Day's High
$6.11
Day's Low
$6.00
Volume
23,610
Avg. Vol
224,848
52-wk High
$9.40
52-wk Low
$1.47

Latest Key Developments (Source: Significant Developments)

Conatus announces effectiveness of exclusive license with Novartis
Thursday, 6 Jul 2017 04:05pm EDT 

July 6 (Reuters) - Conatus Pharmaceuticals Inc -:Conatus Pharmaceuticals - exclusive license with Novartis for global development and commercialization of emricasan has become effective under terms.Conatus Pharmaceuticals - projecting a balance of cash, cash equivalents and marketable securities of between $55 million and $65 million at year-end 2017.Conatus Pharmaceuticals Inc - license became effective on July 5, 2017, upon conatus' receipt of a $7 million payment.Conatus Pharmaceuticals - believes current financial resources sufficient to maintain operations & ongoing clinical development activities through 2019 end.  Full Article

FDA grants Conatus orphan drug designation for idn-7314 for the treatment of PSC
Monday, 26 Jun 2017 07:00am EDT 

June 26 (Reuters) - Conatus Pharmaceuticals Inc ::FDA grants conatus orphan drug designation for idn-7314 for the treatment of PSC.  Full Article

Conatus prices offering of 5.20 mln shares at $5.50/shr
Thursday, 11 May 2017 09:02am EDT 

May 11 (Reuters) - Conatus Pharmaceuticals Inc ::Conatus announces pricing of public offering of common stock.Says public offering of 5.20 million common shares priced at $5.50 per share.Intends to use about $16.7 million of gross proceeds from offering to fund pipeline expansion and for working capital.  Full Article

Conatus Pharmaceuticals Q1 revenue $7.0 million
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Conatus Pharmaceuticals Inc :Conatus Pharmaceuticals reports first quarter 2017 financial results and program updates.Q1 revenue $7.0 million.Q1 revenue view $4.1 million -- Thomson Reuters I/B/E/S.Conatus Pharmaceuticals - current financial resources are sufficient to maintain operations and ongoing clinical development activities through end of 2019.Conatus Pharmaceuticals Inc qtrly net loss at $0.14 per share.Q1 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.  Full Article

Conatus Pharmaceuticals says appointed Steven Mento as acting principal financial officer on March 16
Tuesday, 21 Mar 2017 04:24pm EDT 

Conatus Pharmaceuticals Inc :Conatus Pharmaceuticals Inc - on March 16, board appointed Steven Mento as company's acting principal financial officer.  Full Article

Conatus Pharma qtrly loss per share $0.35
Wednesday, 15 Mar 2017 04:05pm EDT 

Conatus Pharmaceuticals Inc : Conatus pharmaceuticals reports 2016 financial results and program updates . Q4 revenue $800,000 . Q4 revenue view $1.7 million -- Thomson Reuters I/B/E/S .Qtrly loss per share $0.35.  Full Article

Conatus Pharmaceuticals says cfo Charles Cashion resigned
Friday, 17 Feb 2017 04:22pm EST 

Conatus Pharmaceuticals Inc :On February 16, 2017, Charles J. Cashion tendered his resignation as chief financial officer.  Full Article

Conatus Pharmaceuticals Inc qtrly loss per share $0.30
Wednesday, 3 Aug 2016 04:05pm EDT 

Conatus Pharmaceuticals Inc : Conatus pharmaceuticals reports second quarter 2016 financial results and program updates . Conatus pharmaceuticals inc qtrly loss per share $0.30 .Q2 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.  Full Article

Conatus Pharmaceuticals Inc announces results from Multicenter Phase 2 Portal Hypertension Clinical Trial
Wednesday, 23 Sep 2015 04:01pm EDT 

Conatus Pharmaceuticals Inc:Exploratory Phase 2 Portal Hypertension (PH) clinical trial of emricasan, a first-in-class, orally active pan-caspase inhibitor, met the following primary endpoints.Portal hypertension, or elevated blood pressure in the major vein feeding into the liver, was confirmed by HVPG measurement >5 mmHg at baseline and measured again after treatment with 25 mg of emricasan orally twice daily for 28 days.  Full Article

BRIEF-Conatus announces effectiveness of exclusive license with Novartis

* Conatus Pharmaceuticals - exclusive license with Novartis for global development and commercialization of emricasan has become effective under terms